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The adaptive immune system has been the main focus of immunological strategies in oncology with only more recent approaches targeting
ivate innate immune responses by signaling damage-associated molecularnnate immunity. Endosomal toll-like receptors (TLR-7, TLR-9) actatterns (DAMP) from decaying tumor cells. This has led to the development of DNA-based TLR-9 agonists, which induce antitumor activity
hrough innate and subsequent adaptive immune responses. Early clinical trials with CpG-ODN as TLR-9 agonists were associated with
nfavorable tolerability and narrow clinical efficacy, leading to failure in pivotal trials. dSLIM®, the active ingredient of MGN1703, is a
NA-based, radically different molecular alternative to CpG-ODN, which results in genuine antitumor immunomodulation. Preclinical and
∗ Corresponding author. Tel.: +49 30 83871501; fax: +49 30 83871541.
E-mail address: bw@zedat.fu-berlin.de (B. Wittig).
ttp://dx.doi.org/10.1016/j.critrevonc.2014.12.002
040-8428/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
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linical studies of MGN1703 have confirmed that this TLR-9 agonist has therapeutic potential in a variety of solid tumors, while long-term
reatment with high doses was very well tolerated. A pivotal trial of first-line maintenance treatment with MGN1703 in patients with metastatic
olorectal cancer is underway.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
http://creativecommons.org/licenses/by-nc-nd/4.0/).
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.  Introduction
There is a growing recognition that the immune sys-
em plays a key role in the regulation of tumor growth and
evelopment. Components from both the innate and adaptive
mmune systems are involved and cell types such as natural
iller cells (NK), natural killer T cells (NKT), dendritic cells
DC), macrophages, polymorphonuclear leukocytes, mast
ells, myeloid-derived suppressor cells, T lymphocytes and B
ymphocytes all have roles to play [1,2]. Some of these com-
onents inhibit the growth of cancer cells, resulting in their
ventual death in a process known as immunosurveillance
3,4], however, others promote tumor development leading
o a complicated balancing act between pro- and antitumor
mmunity (Table 1) [1,3].
This dual, and seemingly contradictory, functionality
f the immune system was initially described by the
mmunoediting hypothesis, which included three phases:
limination, equilibrium and escape [5]. During the elimi-
ation phase, both an innate and adaptive immune response
s triggered which may eliminate the tumor, whilst during
he equilibrium phase, those cancer cells which were not
liminated persist in dynamic interaction with the immune
ystem. Finally, the escape phase represents a period when
umor cells evade elimination by the immune system and the
ancer progresses [5]. More recently the cancer stem cell,
r the tumor initiating cell (TIC) hypothesis model has been
escribed. Here, a small subfraction of TIC form a homoge-
eous stem cell-like population driving tumor maintenance
nd metastatic formation [6]. Evidence also suggests that
IC are not static, but can evolve and acquire additional
enetic mutations and epigenetic modifications resulting in
able 1
nnate and adaptive immune cells involved in regulating tumor growth [1,3].
timulate cancer growth Inhibit cancer growth
nnate immune cells
Neutrophils DC
Macrophage (M2) Macrophage (M1)
Myeloid-derived suppressor cells NK cells
daptive immune cells
Th2 CD4+ T cell Cytotoxic CD8+ T cell
CD4+ T regulatory cell Th1 CD4+ T cell
Th17 CD4+ T cell
ridge both innate and adaptive systems
NKT (type 2) NKT (type 1)
C, dendritic cell; NK, natural killer; NKT, NK T cells; Th, T-helper.
T
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oti-cancer immunomodulation; Colorectal cancer
ubclones, which consist of functionally different cells. Such
unctional diversity could also contribute to drug resistance,
ith chemotherapy leading to a selection of cells conferring
urvival advantages [6].
A number of immunologic approaches to treat cancer are
ased around activation of the endogenous adaptive immune
esponse. One example is passive immunization, or adop-
ive cell therapy (ACT), which involves the transfusion of
utologous or allogeneic T cells into a patient [7]. A vari-
ty of ACT methods are under investigation and the most
eveloped of these is termed tumor-infiltrating lymphocyte
TIL) therapy [8]. Tumor-specific T cells are harvested from a
iopsy specimen and cultured in vitro in the presence of inter-
eukin (IL)-2 to promote growth. Following chemotherapy
nd/or radiotherapy to eradicate circulating lymphocytes, the
atient receives a transfusion of the cultured T cells which can
hen induce a concerted antitumor response [7]. TIL therapy
as shown promise in the treatment of metastatic melanoma
9]. Other methods of ACT are currently in development
nd clinical trials are ongoing in a wide range of cancers
10].
Active immunization through vaccination is another
pproach and encouraging results have been seen in prostate
ancer with the vaccine sipuleucel-T. This immunotherapy
roduct is prepared using a patient’s own antigen presenting
ells (APC), which are harvested and cultured ex vivo with
 prostate antigen-containing fusion protein PA2024. T-cell
mmunity to the prostate antigen is induced via inclusion of
ranulocyte-macrophage colony-stimulating factor [11,12].
wo studies demonstrated that immunization with sipuleucel-
 extended median overall survival (OS) in comparison to
lacebo [11,12], which led to Food and Drug Administration
FDA) approval of this cancer vaccine.
A third approach involves blocking regulatory check-
oints such as cytotoxic T-lymphocyte-associated antigen-4
CTLA-4) or the programmed death-1 pathway and associ-
ted programmed death ligand 1 (PD-L1), which all limit
he T-cell response and are therefore targets for cancer
mmunotherapy [13,14]. Fully human monoclonal antibod-
es directed against CTLA-4 have been developed, with the
ost widely studied being ipilimumab [15]. In patients with
etastatic melanoma, this treatment has been reported to
xtend median OS [16], and ipilimumab has consequently
een approved by the FDA for this indication. It is also being
nvestigated in a variety of other cancers [15]. Development
f a number of similar monoclonal antibodies is currently
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ngoing, with nivolumab and lambrolizumab being the most
dvanced [13].
In addition to these three approaches, research is ongo-
ng to investigate aspects of the innate immune response
s potential targets for cancer therapies. During tumor cell
eath, a variety of molecules are dispersed that act as sig-
als to the innate immune system warning of damage or
anger [2]. Known as damage-associated molecular pattern
olecules (DAMP), they are recognized by a variety of recep-
ors, including the toll-like receptors (TLR) found on innate
mmune cells, resulting in activation of a cancer-associated
nflammatory response [2,17]. While the interplay between
ancer-derived DAMP and TLR is complex, this represents
n alternative developmental area for cancer immunotherapy
ptions.
More recently, several innate lymphoid cells have been
dentified including NK cells, which can distinguish stressed
ells from healthy cells via recognition of up-regulated acti-
ating ligands. Such recognition results in the secretion of
ro-inflammatory cytokines or can promote direct NK-cell
ediated cytotoxicity [18]. Invariant NKT (iNKT) cells have
een shown to function as both innate cells and memory
ells via expression of a semi-variant T cell receptor. iNKT
ells can be indirectly activated by high amounts of pro-
nflammatory cytokines and in this setting resemble NK cells
nd produce a T-helper (Th)1-type cytokine response [18].
This review focuses on the role TLR play as sensing mod-
lators of the innate immune system and the therapeutic
otential of targeting one specific member of this protein
amily, TLR-9, with the TLR-9 agonist MGN1703 which
as now entered Phase III trials in the first-line/maintenance
etting in patients with metastatic CRC (Immunomodu-
atory MGN1703 [IMPALA]; ClinicalTrials.gov Identifier:
CT02077868).
.  Damage-associated  molecular  pattern  molecules
DAMP)
One of the key processes of the non-infectious inflamma-
ory response involves the release of DAMP, which may be
roduced in response to a variety of stimuli including cel-
ular injury, necrotic cell death, ischemia and other stress
actors [19]. A cascade of signaling events, termed signal 0
o signal 5, is triggered by the presence of DAMP [17]. The
ignal 0 events induce the early innate immune responses
hrough a variety of receptors and ligands, which facilitate the
ignaling through triggers of inflammation, such as cytokines
nd chemokines, ultimately culminating in a full immune
esponse [17,19].
As discussed, a host of different inflammatory cells are
nown to be activated in the presence of malignant cells
17,20]. However, if this acute inflammatory response is
nsufficient to fully destroy the developing tumor, a dys-
egulation of the immune system can occur, resulting in
 chronic inflammatory response typified by production of
b
i
t
logy/Hematology 94 (2015) 31–44 33
arge numbers of certain innate immune cells that can ulti-
ately promote the growth and progression of cancer [17,20].
t has been suggested that DAMP-like re-arranged mem-
rane components, nuclear-, cytoplasmic-, and mitochondrial
roteins as well as DNA from damaged mitochondria and
leaved chromatin, are released following tumor cell decay,
nd contribute to this dysregulation. In turn, this may help
o perpetuate a favorable environment for tumor prolifer-
tion [17]. Specific DAMP appear to be associated with
ertain types of malignancy. Typical examples include the
igh mobility group box 1 and S100 proteins which have been
inked to cancers of the breast, liver, oral cavity, prostate and
enitalia [21].
Generally found on the surface of micro-organisms,
athogen-associated molecular pattern molecules (PAMP)
llow the innate immune system to recognize and respond
o an invading pathogen [17]. Similar to DAMP, and in addi-
ion to being part of the infectious immune response, some
AMP are also associated with a range of different types of
ancer [21].
Both DAMP and PAMP may be bound by the same trans-
embrane pattern recognition receptors (PRR), in particular
y various members of the TLR family, albeit by different
echanisms [21,22]. Binding of these molecules to TLR
esults in the induction of TLR signaling pathways, thereby
romoting an inflammatory response [22]. However, in the
resence of tumor cells, dysregulation of TLR signaling can
lso create an environment conducive for tumor growth [23].
onsequently, TLR and TLR signaling is an increasing area
f interest for the development of new antitumor agents.
. Toll-like  receptor  9  (TLR-9)
TLR are a key component of the innate immune sys-
em and are essential for the recognition of PAMP and/or
AMP. TLR belong to the type 1 transmembrane glyco-
roteins. Currently ten human TLR (TLR-1 to TLR-10) have
een identified, which differ according to their cellular loca-
ion and varied activating ligands [24,25]. This section will
ocus on TLR-9, which is the TLR with the narrowest tis-
ue distribution. In resting human immune cells, it is only
xpressed on B cells and plasmacytoid dendritic cells [26].
pon cell activation, TLR-9 can also be found in neutrophils,
onocytes and T cells [27].
TLR-9 is activated by non-methylated CG motifs from
ucleotide sequences. Non-methylated CG motifs are com-
on in bacterial and viral genomes, but occur infrequently
n mammalian DNA [28,29]. Where CG motifs do occur
n mammalian DNA, they tend to be methylated [28]. The
xception is mitochondrial DNA (mtDNA), since mitochon-
ria are evolutionary endosymbionts that were derived from
acteria [30]. Injury/trauma releases mitochondrial DAMP –
.e., non-methylated CG motifs – into the circulation. Given
hat they are derived from mtDNA, these DAMP have evo-
utionarily conserved similarities to bacterial PAMP [31].
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onsequently, the non-methylated CG motifs cause a strong
mmune response, which is mediated primarily by TLR-9
28,30–33]. To date, TLR-9 appears to be the only TLR that
s activated by non-methylated CG motifs from mitochondrial
AMP.
The activation of TLR-9 by non-methylated CG
otifs was first demonstrated by studies performed in
 murine model [28]. When challenged with CpG-
ligodeoxynucleotides (CpG-ODN), TLR-9-deficient mice
id not induce typical immune responses seen in wild-type
ice [28]. Increased proliferation of splenocytes or produc-
ion of inflammatory cytokines from macrophages were not
bserved in the TLR-9-deficient mice, even after further
timulation with interferon (IFN)-gamma. Additionally, the
aturation of DC did not occur, there was a lack of expres-
ion of surface molecules CD40, CD80, CD86 and major
istocompatibility complex (MHC) class II, and the T-helper
ype-1 response was absent. These findings demonstrated
hat the presence of CpG-ODN in a cell triggers a mecha-
ism to initiate binding with TLR-9 and ultimately signal
ransduction.
TLR-9 is located in the endoplasmic reticulum, primar-
ly in plasmacytoid DC (pDC), where the functional role of
his receptor has been proven. TLR-9 is also expressed on
he majority of innate and adaptive (CD4+, CD8+, NKT and
[
i
u
ig. 1. Signaling pathway following TLR-9 activation [26]. On internalization, Cp
DC, spatiotemporal regulation impacts downstream signaling cascades and the r
ith TLR-9 occurs in early endosomes. Recruitment of the adapter protein MyD8
ctivation of IRF7, resulting in high IFN-alpha levels. (B) In contrast, Type B CpG
LR-9 culminates in activation of the NF-B pathway and secretion of a number o
ne or more non-methylated CG motifs; IRAK, interleukin-1R-associated kinase
esponse 88 adaptor protein; NF-B, nuclear factor kappa B; pDC, plasmacytoid
eceptor-associated factor.ogy/Hematology 94 (2015) 31–44
  T) effector cells [27], where its function is less clear,
nd in B cells [24,34,35]. Transport of CpG-ODN inter-
ally into the endosomal/lysosomal compartment of the cell
ccurs via endocytosis in human resting cells [36,37]. It is
hought that an endoplasmic reticulum membrane protein,
NC93B1, then recruits TLR-9 and delivers it to the same
ysosomal compartment, where it binds directly to CpG-ODN
36–39]. Following this binding, TLR-9 engages with the
yeloid differentiation primary response 88 adaptor pro-
ein, which triggers a distinct signaling pathway [24,36].
ransduction molecules activated in this cascade include
nterleukin-1R-associated kinases and tumor necrosis fac-
or receptor-associated factor 6 [40]. In turn, this stimulates
oth the nuclear factor kappa B and IFN regulatory factor-
 pathways, resulting in production of pro-inflammatory
ytokines and type I IFN, respectively [29,40]. An overview
f the signaling pathway and immunologic response follow-
ng TLR-9 activation is summarized in Fig. 1.
TLR are also involved in linking the innate to the adaptive
mmune response; although they are classified as transmem-
rane PRR of the innate immune system, they can activate
lasses of cells associated with the adaptive immune system
41]. The development of mature APC from immature DC
s facilitated by TLR. This results in induction of costim-
latory molecules such as CD40, CD80 and CD86, which
G-ODN encounter TLR-9 located in the endolysosomal compartment. In
esulting cytokine profile. (A) Long-term encounter of Type A CpG-ODN
8 by activated TLR-9 initiates downstream signaling via IRAK/TRAF and
-ODN is quickly transferred to lysosomal vesicles. Here, encounter with
f inflammatory cytokines. CpG-ODN, Oligodeoxynucleotide(s) containing
; IRF7, IFN regulatory factor 7; MyD88, myeloid differentiation primary
 dendritic cell; TLR-9, toll-like receptor 9; TRAF, tumor necrosis factor
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re components of the T-cell activation process [24]. In addi-
ion, T-cell differentiation into CD4+ T-helper type 1 or CD8+
ytotoxic lymphocytes is directed by TLR-induced cytokines
24]. The involvement of TLR in both the innate and adaptive
mmune response suggests that they may be useful targets for
mmunotherapy.
.  Toll-like  receptor  9  (TLR-9)  agonists  in  tumor
mmunotherapy
Bacteria or bacterial extracts associated with non-
ethylated CG motifs have long been known to possess
ntitumor activity, as well as to have a powerful effect on
he immune system [42–44]. In addition, it is known that
uring tumor cell death, mtDNA and mitochondrial formyl
eptides are released, which may act as DAMP and poten-
ially result in the dysregulation of TLR-9 [2]. Therefore,
hile complex, there does appear to be a role of TLR-9 in the
evelopment of some tumors. For example, a study by Eiró
t al. found a potential protective role of TLR-9 expression
gainst malignant transformation in the colorectal mucosa:
LR-9 expression was decreased in hyperplastic and villous
olyps from patients who developed colorectal cancer (CRC)
45]. TLR-9 has also been shown to be associated with certain
ther tumors [26].
As a consequence, TLR-9 has become a target of inves-
igation for various malignancies [46,47]. In this regard,
evelopment of synthetic ODN containing non-methylated
G motifs has been the cornerstone of research into TLR-9
gonists for tumor immunotherapy [46,48]. As native DNA
s subject to degradation by nucleases, synthetic CpG-ODN
ay be modified to enhance stability. For example, one
pproach is for the normal phosphodiester component of the
ackbone of DNA to be replaced by a nuclease-resistant phos-
horothioate (PT), which increases the half-life from a few
inutes to around 2 days [48]. CpG-ODN can be classified
nto three separate classes with different structural character-
stics and differentially enhancing antigen-specific humoral
nd cellular immune responses [49,50]: Class A are strong
nducers of IFN-alpha from pDC but very poor B cell acti-
ators, Class B are potent stimulators of B cell proliferation
ith poor induction of pDC IFN-alpha secretion, while Class
 CpG-ODN exhibit moderate properties from both Class A
nd Class B [49].
To date, the most widely studied CpG-ODN TLR-9
gonist has been PF-3512676, which is a Class B, single-
tranded agent (also known as ProMune, CpG-7909 or
DN2006). Investigation of PF-3512676 monotherapy in a
ariety of cancers has shown mixed results [47,51–55]. In
1 patients with chronic lymphocytic leukemia no clinical
esponse was reported following PF-3512676 given as an
ntravenous (i.v.) infusion (1.05 mg/kg) or subcutaneously
0.45 mg/kg) [55]. Similarly, 23 non-Hodgkin lymphoma
atients administered with i.v. PF-3512676 at doses up to
.64 mg/kg showed no clinical response at day 42, although
d
f
l
sogy/Hematology 94 (2015) 31–44 35
wo patients demonstrated late response [52]. Some activity
as seen in a phase II trial of 20 patients with metastatic
elanoma, who received 6 mg PF-3512676 subcutaneously
53]. Two partial responses (PR) were reported, one of
hich continued for >140 weeks, along with an additional
hree patients achieving stable disease (SD). Similarly, some
ctivity was seen in a phase I dose-escalating trial in patients
ith cutaneous T cell lymphoma (51). Twenty-eight patients
eceived up to 0.36 mg/kg of subcutaneous PF-3512676
nd three complete responses (CR) were reported along
ith six PR. Finally, 39 patients with stage IV renal cell
arcinoma receiving subcutaneous PF-3512676 at doses up
o 0.81 mg/kg in a phase I/II study reported two PR [54].
Combination trials of PF-3512676 administered in con-
unction with standard chemotherapy regimens as first-line
reatment in advanced non-small-cell lung cancer have not
hown improvement over the monotherapy trials mentioned
bove. A phase III study comparing PF-3512676 with or
ithout paclitaxel/carboplatin reported no improvements
n median OS (10.0 months versus 9.8 months; P  = 0.56)
r median progression-free survival (PFS) (4.8 months
ersus 4.7 months; P = 0.79; [56]). A second, similar phase
II study comparing PF-3512676 with or without gemc-
tabine/cisplatin also showed little difference in median OS
11.0 months versus 10.7 months; P  = 0.98) and no differ-
nce in median PFS (both groups were 5.1 months) [57]. In
ddition, both studies revealed a higher proportion of adverse
vents (AE) ≥  grade 3 in patients receiving PF-3512676. Due
o the lack of significantly improved efficacy and increased
oxicity seen with PF-3512676, both trials were terminated
arly due to an unfavorable risk-benefit profile [56,57].
In order to improve efficacy and reduce toxicity, struc-
ural changes were made to CpG-ODN, including linking
wo CpG-ODN with their 3′-ends and through the inclu-
ion of novel synthetic immunostimulatory motifs [26]. This
esulted in the development of the second-generation TLR-9
gonist, IMO-2055. A phase I study administering IM0-2055
lus gemcitabine/carboplatin to 18 patients with solid tumors
eported a single case of PR [58]. A second phase Ib trial com-
ining IMO-2055 with 5-fluorouracil/cisplatin/cetuximab in
3 patients with recurrent or metastatic squamous cell carci-
oma of the head and neck reported three patients achieving
R and nine patients with SD [59]. However, as serious AE
ccurred in eight patients, four of which were deemed to
e related to IMO-2055, and one patient died, the trial was
topped prematurely. Additionally, a phase II trial in this
ndication, did not meet its primary endpoint of improved
FS following treatment with IMO-2055 in combination with
etuximab compared to treatment with cetuximab alone [60].
Given the results described above, it is unsurprising that
t the present time, no CpG-ODN has been approved in
n oncology indication. This demonstrates the need for the
evelopment of an alternative, next generation TLR-9 agonist
or cancer therapy. In this respect, the family of double-stem
oop immunomodulators (dSLIM), such as MGN1703, has
hown promise. These agents also include CG motifs within
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Fig. 2. Descriptive secondary structure of MGN1703 [62]. MGN1703 is a
member of the dSLIM family exhibiting a double stem of 28 base pairs and
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iwo loops with 30 nucleotides – each containing three CG motifs (circled).
SLIM, double-stem loop immunomodulator.
heir structure. However, they are structurally distinct from
pG-ODN; they are double-stranded rather than linear and
nclude a natural phosphodiester, rather than a phosphoro-
hioate backbone [47,61,62]. It has been proposed that this
ovel structure may improve activity and lead to improved
oxicity versus earlier TLR-9 agonists. The following sec-
ion describes the development of MGN1703, including a
ummary of preclinical and clinical results reported with the
gent.
.  Preclinical  characteristics  of  MGN1703
.1.  Structure  and  physical  characteristics  of  MGN1703
MGN1703 is a small DNA molecule containing 116
ucleotides [61]. The molecule has a covalently closed
umbbell-shaped structure due to a stretch of reverse com-
lementary DNA forming a 28 base pair double-stranded
idsection, flanked at either end by two single-stranded
oops, each containing 30 nucleotides (Fig. 2). Natural
hosphodiester bonds maintain the non-branched structure
nd there are no unnatural components present in the
olecule. Sequences of each loop comprise three effective
on-methylated CG motifs [61,62].
.2.  Biological  effects  of  MGN1703  on  cytokines  and
mmune cells
The structure and sequence of MGN1703 results in a
nique immunomodulation profile with regard to activation
f cells and production of proteins of the immune system
61–63] as specified below. An overview of the mechanism
f action of MGN1703 is shown in Fig. 3.
The effect of MGN1703 on cellular activation of a variety
f components within the peripheral blood mononuclear cell
PBMC) pool was demonstrated by a significantly increased
xpression of specific surface activation markers [61]; CD86
as up-regulated on monocytes, myeloid DC (mDC) and B
ells, CD40 expression was increased on pDC, higher lev-
ls of HLA-DR (MHC class II) were detected on pDC and
DC, CD169 became up-regulated on monocytes, and CD69
evels increased on NK, NKT cells and T cells (Table 2). In
BMC, MGN1703-dependent CD69 up-regulation on NK
o
togy/Hematology 94 (2015) 31–44
ells occurred at the same time as NK-cell mediated cyto-
oxicity increased [61]. This is important for the anti-cancer
ffect of MGN1703, since NK cells are responsible for selec-
ively eliminating harmed cells by inducing apoptosis.
MGN1703 has also been shown to significantly increased
he release of a variety of cytokines and chemokines from
BMC. Secretion from PBMC occurred during the first
8 h of exposure and included IFN-gamma-induced protein
0 (IP-10), IFN-alpha, macrophage inflammatory protein
MIP)-1-alpha, MIP-1-beta, IL-6, IFN-gamma, monocyte
hemotactic protein (MCP)-1 and IL-8 (Table 2) [61].
xpression of IL-12p70, monokine induced by gamma-
nterferon (MIG) and tumor necrosis factor (TNF)-alpha
id not appear to be significantly affected by MGN1703
Table 2).
In terms of establishing the specific cellular targets of
GN1703, isolated TLR-9-positive pDC showed increased
ecretion of IFN-alpha, MIP-1-alpha, MIP-1-beta, IL-6,
NF-alpha and IL-8 following MGN1703 stimulation. Addi-
ionally, activation by MGN1703 of isolated TLR-9-positive
 cells led to increased expression of MIP-1-alpha, IL-6,
NF-alpha and IL-8 compared with incubation with medium
61]. The direct activation of isolated TLR-9-positive cells,
s well as absence of a cellular activation profile evoked by
GN1703 in PBMC populations depleted of either TLR-9-
ositive cell type, strongly point to MGN1703 as a TLR-9
igand. This pharmacological action has been corroborated
n a study of an MGN1703 derivative in which all CG
otifs in both loops were switched to thymidine-guanine
TG) nucleotide sequences. This non-CG MGN1703 no
onger activated pDC nor a reconstructed signaling cascade
n a model cell line with a TLR-9-triggered eGFP expres-
ion (ELAM41 cells) [61]. Furthermore, the activation of
LAM41 cells by MGN1703 was inhibited by chloroquine,
 lysosomotropic agent that prevents endosomal acidification
 a process necessary for TLR-9 signaling [65].
Activation of both the innate and adaptive immune
esponses is known to be associated with increased expres-
ion of type I IFN, including IFN-alpha, from pDC [66,67].
n addition, reports show a link between CD169 expression
n monocytes and the induction of a type I IFN response
68,69]. The data described here show that exposure to
GN1703 significantly increased secretion of IFN-alpha in
DC and expression of CD169 in monocytes, suggesting that
GN1703 has a role to play in activation of components of
oth the innate and adaptive immune systems via the IFN-
lpha pathway (Fig. 3). This is important, since activation of
oth innate and adaptive immune response is believed to be
equired for an effective antitumor response [70].
.3.  Inﬂuence  of  molecule  structure  on  the
mmunomodulatory  effect  of  MGN1703Stem-loop constructs varying in number and distribution
f CG motifs, and stem and loop size, have been studied for
heir immune-stimulatory potential [63]. Notably, molecules
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Fig. 3. Mechanism of action of MGN1703 [64]. (1) MGN1703 activates TLR9-bearing pDC and B cells. (2) IFN-alpha, secreted by pDC, initiates broad
activation of the innate and adaptive immune system: NK cells and NKT cells are activated for cytotoxicity against tumor cells. Monocytes and B cells are
activated. (3) Monocytes secrete cytokines and chemokines: IP-10 is chemotactic for NK cells and inhibits tumor growth through its angiostatic properties.
IFN-alpha, together with IFN-gamma from NK and NKT cells, activates mDC. Furthermore, IFN-gamma regulates the differentiation of T cells. (4) pDC and
mDC take up TAA released from tumor cells decaying due to prior therapies; TAA are presented to T cells. (5) CD4+ helper T cells and CD8+ cytotoxic T
cells for tumor cell elimination are generated by proliferation. (6) IFN-alpha amplifies activation of B cells, resulting in antibody secretion against antigens on
tumor cells which can be eliminated by NK cells via ADCC. See also Table 1. Republished with permission of Springer-Verlag Berlin/Heidelberg, Schmoll HJ
et al., Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and
disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol 2014;140(9):1615–24; permission conveyed
through Copyright Clearance Center, Inc. ADCC, antibody-dependent cell-mediated cytotoxicity; BCR, B cell receptor; CTLA4, cytotoxic T lymphocyte-
a duced 
c  progra
p receptor
w
C
I
m
F
c
d
t
o
k
a
[
5
s
l
w
b
d
1
a
m
l
d
t
a
s
t
e
s
a
r
u
p
l
5ssociated protein 4; IFN, interferon; IL, interleukin; IP-10, IFN-gamma-in
omplex; NK cell, natural killer cell; NKT cell, natural killer T cell; PD-1,
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ith only one loop, CG motifs in only one loop or those with
G motifs in the double-stem, diminished the increase in
FN-alpha secretion from human PBMC or IL-12p40 from
urine spleen cells compared with MGN1703 (Fig. 4A–C).
urthermore, the length of the stem and size of the loop was
ritical; the MGN1703 composition with the 28 base pair
ouble-stem and loop containing 30 nucleotides was iden-
ified as the most effective. This was shown by an increase
f IFN-alpha expression from human PBMC (Fig. 4D). In
eeping with these findings, other reports have also described
 dependence on the secondary structure of the molecule
71,72].
.4.  Differential  effects  of  MGN1703  versus  CpG-ODN
MGN1703 differs from CpG-ODN not only in terms of
equence and structure, but also with respect to pharmaco-
ogical parameters. The TLR-9-positive ELAM41 cell system
as used to measure potency of MGN1703 versus mem-
ers of the CpG-ODN classes: A, B and C [61]. MGN1703
eveloped an EC50 of 0.1 M compared with EC50 of
.5 M (Class A ODN2216), 0.4 M (Class B ODN2006)
e
cprotein 10; mDC, myeloid dendritic cells; MHC, major histocompatibility
mmed cell death protein 1; PD-L1, programmed cell death ligand 1; pDC,
; TNF, tumor necrosis factor.
nd 0.8 M (Class C M362) indicating that MGN1703 is
ore potent than CpG-ODNs in this system (Fig. 5A).
Furthermore, immunological responses in PBMC stimu-
ation of cytokine secretion and activation of immune cells
iffered between MGN1703 and CpG-ODN [61]. Exposure
o MGN1703 and ODN2216 resulted in secretion of IFN-
lpha and IP-10 while MGN1703, ODN2216 and ODN2006
timulated IFN-gamma production (Fig. 5D and E). Activa-
ion of monocytes and NK cells was high after exposure to
ither MGN1703 or ODN2216, whereas ODN2006 demon-
trated very limited activation of either cell type (Fig. 5B
nd C) [61]. In contrast, activation of PBMC with ODN2006
esulted in a very potent secretion of IL-8 – a cytokine
ndesirable in the tumor environment due to its angiogenic
roperties [61]. The extent of this secretion was considerably
ower with MGN1703 and ODN2216 (Fig. 5F).
.5.  Comparison  of  MGN1703  and  CpG-ODN:  toxic
ffects in  mice
It is known that PT-based CpG-ODN result in signifi-
ant toxic effects. Reduced functionality and definition of
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ymphoid organs have been observed in mice studies [73],
nd these effects may have contributed to the unfavorable
isk-benefit profile seen in clinical trials with CpG-ODN, as
escribed above. Studies by Heikenwalder et al. in which
he PT-containing ODN1826 was used, led to similar inves-
igations with MGN1703. Injections of MGN1703 did not
hange liver, spleen or lymph node weight and had only a
light effect on histopathologic changes in liver and spleen
issues. In contrast, ODN1826 led to significant increases in
iver and spleen weight, together with liver toxicity (inflam-
atory reactions and hepatocyte necrosis) and damage to the
pleen [63]. This is in line with results from Heikenwalder
t al. [73] and provides evidence that PT-modifications in
NA-based TLR-9 agonists should be avoided.
.6.  Preclinical  antitumor  activity  of  MGN1703
Preclinical evidence of the antitumor effect of MGN1703
as been reported in several mouse studies. In an SKH1
urine model in which de novo papilloma develop-
ent was initiated and promoted by topical application
f chemicals (7,12-dimethylbenzanthracene and 12-O-
etradecanoylphorbol-13-acetat), MGN1703 significantly
educed the number of mice developing papillomas com-
ared with the saline control group, and the total number of
apillomas on all mice was reduced by approximately 50%
y MGN1703 [74]. Furthermore, several syngeneic murine
umor models were established: a melanoma model with
ubcutaneous or i.v. B16 tumor cell challenge, a lung carci-
oma model with i.v. 3LL tumor cell challenge and a renal
ell carcinoma model with subcutaneous renal tumor cell
hallenge. MGN1703 was applied at least six times prophy-
actically or therapeutically and across all models resulted in
ntitumor effects which were independent of type of tumor
ell challenge. In addition, MGN1703 decreased growth
f solid tumors and reduced the number of metastatic lung
odules [75]. A cell-based tumor vaccine containing tumor
ells modified to express IL-7, granulocyte-macrophage
olony stimulating factor (GM-CSF), CD80 and CD154 in a
xed combination with MGN1703 used in a murine model
or renal cell carcinoma showed 92% survival compared
ith 25% survival in the control group. This activity was
ssociated with augmented T cell proliferation (>6-fold),
ytotoxic activity against spleen cells (>3-fold), and an
ncrease of CD4+, CD8+ and CD86+ cells at the vaccination
ite (up to 20-fold) [76].
.  Clinical  investigation  of  MGN1703  in  patients  with
ancer
.1.  Phase  I  studies  in  solid  tumors:  MGN1703  as  a
accine adjuvant
MGN1703 was investigated in two studies at very low
oses as an adjuvant to vaccination. The first phase I study
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Fig. 4. Influence of structure on function of MGN1703 [63]. (A) Schematic drawing of MGN1703 and various modifications (Mod-1 to -3) with CG motifs
in black. (B) Activation of normal donor PBMC to produce IFN-alpha. (C) Activation of IL-12p40 production by murine spleen cells. (D) Schematic draw of
MGN1703 and different sized modifications (Mod-4 to -7) with CG motifs in black (left). Numbers of nucleotides is denoted in the loops. Number of base pairs
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rom the same donor. Reprinted by permission from Mary Ann Liebert, Inc.,
gonistic immunomodulator MGN1703. Nucleic Acid Ther 2015, in press, 
f MGN1703 was performed in 10 patients with metastatic
olon carcinoma, renal cancer or melanoma [77]. Four sub-
utaneous vaccinations of autologous tumor cells modified
o express IL-7 and GM-CSF were administered in com-
ination with MGN1703. Treatment was associated with
ncouraging activity: one CR (>24 months), one PR and
ne mixed response with progression of abdominal metas-
ases but regression of lung metastases. In addition, two
atients achieved SD and a further five showed progressive
isease (PD) (Table 3). Importantly, AE were not reported
n any patient [77]. A second phase I/II study investigated
GN1703 in combination with vaccination and chemother-
py in 17 patients with metastatic CRC [78]. Patients were
reated on an alternating schedule of two vaccinations one
eek apart, followed by a cycle of standard chemotherapy.
his pattern was followed for 3 cycles of chemotherapy
nd after completion, patients continued to receive weekly
accinations until PD occurred. In this study, patients were
andomized to a number of adjuvant-containing vaccinations.
GN1703-containing vaccines were given to 9/17 patients.
n detail, five patients (29%) achieved a CR (four receiv-
ng an MGN1703 vaccine), one (6%) a PR, five (29%) had
D (four receiving an MGN1703 vaccine) and six patients
36%) showed PD (one receiving an MGN1703 vaccine)
Table 3). Overall, AE reported were few in number and
f a mild grade [78]. Vaccinations were generally well
olerated only led to mild and transient side effects such as
t
S
s
Alpha (right). Samples were analyzed by ELISA. Lines connect the samples
t M, et al. Design and structural requirements of the potent and safe TLR-9
ht 2015.
ocal skin reactions or short-term body temperature elevation
78].
.2.  Phase  I  study  in  metastatic  solid  tumors:  MGN1703
s a  therapeutic  drug
A subsequent open-label phase I dose-finding study has
lso been completed that evaluated the safety and toxicity of
igher doses of MGN1703 in 28 patients with metastatic solid
umors who had failed standard therapy [79]. The study had
wo parts; a single-dose phase (15 patients) and a multiple-
ose phase (24 patients, 11 of which were included from
he single-dose phase), with MGN1703 administered sub-
utaneously at dose levels of 0.25–60 mg in each phase.
n the multiple-dose phase, subcutaneous MGN1703 was
dministered on a twice weekly basis for 6 weeks with the
ossibility of a further 6 week extension after disease sta-
ilization followed by compassionate use (on request of the
nvestigators). The maximum-tolerated dose was not reached,
espite patients receiving the highest dose allowed of 60 mg.
he most frequent drug-related AE were generally mild and
id not result in any discontinuations. Six out of 15 patients
40%) who received treatment for 6 weeks had SD with
he remainder showing PD (Table 3). The six patients with
D continued in the extension phase of whom three (50%)
howed SD after 6 further weeks of MGN1703 treatment.
 total of four patients were then allowed to continue into
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Fig. 5. Immunomodulatory effects of MGN1703 compared with different CpG-ODN [61]. (A) Potency of MGN1703 compared with various CpG-ODN from
each class. ELAM41 cells were stimulated with increasing concentrations of MGN1703 or CpG-ODN. (B, C) Effect of MGN1703 and CpG-ODN on activation
o etion. *
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0; MFI, mean fluorescence intensity; NK, natural killer; NS, not-significan
td, Kapp K, et al. Genuine immunomodulation with dSLIM. Mol Ther–Nu
ompassionate use. Of these, three patients demonstrated
rolonged SD with non-small-cell lung cancer (18 months),
elanoma (15 months) and CRC (6 months). A fourth patient
ith CRC achieved almost PR (29.7% of tumor reduction)
uring this time and continued treatment for 17 months until
isease progression [79]. Immunological assessments in this
tudy revealed that treatment with MGN1703 was associated
ith an increase in the relative number of TLR-9-expressing
aïve B cells and a reduction in memory B cells. In addi-
ion, a relative increase in the percentage of pDC compared
ith mDC was reported. Taken together, these early phasetudies showed that MGN1703 was well tolerated at doses
p to 60 mg and was associated with encouraging activ-
ty along with evidence of immune activation in heavily
fi
r
a
dP < 0.05; ***P < 0.001. IFN, interferon; IP-10, IFN-gamma-induced protein
ol, unstimulated cells. Reprinted by permission from Macmillan Publishers
s 2014;3:e170, copyright 2014.
retreated patients with solid tumors, and CRC in particular
79].
.3.  Phase  II  trial  of  MGN1703  in  patients  with
dvanced  CRC  (IMPACT)
Following on from the promising phase I trial results,
 double-blind phase II trial was performed to evaluate
GN1703 in the maintenance setting for patients who had
chieved disease control of metastatic CRC after standard
rst-line induction therapy [64]. A total of 59 patients were
andomized in a 2:1 ratio to receive subcutaneous MGN1703
t a dose of 60 mg or placebo, both given twice weekly until
isease progression [64].
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Table 3
Clinical responses achieved with MGN1703 in trials to date.
Study Number of patients
receiving MGN1703
Indication Response for patients
receiving MGN1703
Reference
Phase I vaccination
(n = 10)
10 Metastatic colon
carcinoma, renal
cancer or melanoma
1 CR, 1 PR, 1 mixed
response, 2 SD, 5 PD
Wittig et al. (2001)
[77]
Phase I/II randomized
vaccination followed by
chemotherapy
(n = 17)
9 Metastatic CRC 4 CR, 4 SD, 1 PD Weihrauch et al.
(2005) [78]
Phase I monotherapy
(n = 28)
24 (28 including
single dose group)
Metastatic solid
tumors
6 SD, 5 not evaluablea
(1 patient achieved
almost PR during
compassionate use),
13 PD
Weihrauch et al.
(2014) [79]
Phase II double-blind
MGN1703 versus placebo
(n = 59)
43 Metastatic CRC All patients had at
least SD at inclusion
(endpoint: PFS);
3 objective responses
Schmoll et al. (2014)
[64]
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a Reasons for drop-out of the 5 patients: 2 for regulatory reasons, 2 for pr
MGN1703 maintenance treatment was associated with
urable PFS in some patients. For the primary endpoint
f PFS from the date of randomization to progression on
aintenance therapy, hazard ratios (HR) were 0.55 (95%
onfidence interval [CI], 0.3–1.0; P  = 0.04) and 0.56 (95%
I, 0.29–1.08; P  = 0.07) following investigator and indepen-
ent review, respectively [64]. The median PFS was 2.8
onths (95% CI, 2.8–4.1) with MGN1703 maintenance and
.6 months (95% CI, 2.5–2.8) with placebo. When measured
rom the start of induction therapy, PFS statistically signif-
cantly improved with MGN1703 compared with placebo
ollowing both independent and investigator assessment [64].
Additional subgroup analyses of the primary endpoint
uggest that the greatest benefit of MGN1703 may be in
atients with a relatively low tumor burden [64]. In this
egard, patients with a reduction in tumor size at the end of
nduction therapy greater than the median (HR 1.015; 95%
I, 1.002–1.029; P  = 0.024), or a CEA concentration within
he normal range at the end of induction therapy (HR 0.326;
5% CI, 0.159–0.668; P  = 0.002) had an increased PFS versus
atients without these characteristics [64]. However, given
he small numbers of patients in this study, these data should
e treated cautiously.
At the time of analysis, OS data were not mature. How-
ver, the median OS from randomization was 22.6 months
95% CI, 14.9 – not reached) with MGN1703 maintenance
nd 15.1 months (95% CI, 10.6 – not reached) with placebo
HR 0.63; 95% CI, 0.3–1.5; P  = 0.3) [64]. The median OS
rom the start of induction was 26.3 months (95% CI, 21.0
 not reached) with MGN1703 and 21.2 months (95% CI,
6.5 – not reached) with placebo (HR 0.65; 95% CI, 0.3–1.6;
 = 0.3).
Three patients in the MGN1703 group had a con-
rmed objective tumor response (objective response rate
.0%) during maintenance treatment compared with one
a
i
tal response; SD, stable disease.
eviations, 1 withdrawal of consent.
lacebo-treated patient. Two of the three MGN1703 patients
chieved a response only after 9 months of MGN1703
onotherapy, indicating that a carry-over effect from the
nduction therapy was highly unlikely. At the time of
he reported analysis, four patients remained stable having
een receiving MGN1703 maintenance for 16–30 months
Table 3) [64].
In a pre-planned analysis of potential immunological
iomarkers, the effects of MGN1703 treatment on cellular
ctivation of immunostimulatory cells were apparent with a
redominant increase in activated monocytes and pDC [64].
mong patients with high activated NKT cell counts at base-
ine, MGN1703 led to significantly greater PFS relative to
lacebo (HR 0.27; 95% CI, 0.14–0.82; P  = 0.007). Although
onfirmatory data are needed, this suggests that activated
KT cells may be a biomarker for selecting patients most
ikely to benefit from MGN1703 therapy.
In terms of safety and tolerability, a higher proportion of
atients receiving MGN1703 experienced a treatment-related
E relative to placebo (79% versus 38%, respectively). How-
ver, treatment-related AE tended to be mainly grade 1 or
, with one patient discontinuing MGN1703 therapy due to
n AE (sensory neuropathy). However, this patient received
xaliplatin chemotherapy before the study. Treatment-related
E of interest because of the MGN1703 mode of action
r administration were also mild and included fever (n  = 5),
atigue (n  = 4) and injection-site pruritus (n  = 4) [64]. Only
ne serious AE was assessed as possibly related to MGN1703
a patient developed atypical pneumonia with moderate
ymptoms and was submitted to hospital to confirm diag-
osis).
The findings from this phase II study are encouraging,
nd indicate that maintenance therapy with MGN1703 may
mprove PFS compared with placebo in advanced CRC, par-
icularly in certain subgroups of patients. In agreement with
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arlier studies, MGN1703 was also found to be well tol-
rated, suggesting that the tolerability profile of this agent
s more in line with that of therapeutic vaccines (e.g.,
ipuleucel-T) rather than the single-stranded TLR-agonists
e.g., PF-3512676). The absence of significant systemic tox-
city of MGN1703 may potentially be due its composition of
nly natural (i.e., non-modified) DNA.
.  Conclusions
The development of TLR-9 agonists in cancer
mmunotherapy is ongoing with research mainly being
irected at a variety of ODN. Despite some initial promise,
arly generation molecules have not yet been successful
n oncology. For example, two phase III trials of the ODN
F-3512676 combined with chemotherapy in non-small
ell lung cancer were halted early for futility and the
igher incidence of toxicity in the PF-3512676 arm [56,57].
urthermore, the development of another ODN, IMO-2055,
as stalled after the addition of IMO-2055 to cetuximab
ailed to improve PFS in patients with recurrent or metastatic
quamous cell cancer of the head and neck [60].
Compared with CpG-ODN molecules, MGN1703 has a
ovel structure, resulting in differential stimulation of the
mmune system compared with the standard classes of CpG-
DN [61]. Additionally, MGN1703 contains only natural
NA components. Clinical trials to date demonstrate that
GN1703 is well tolerated, with mainly grade 1 or grade
 AE. Promising signs of efficacy have also been reported
n a variety of solid tumors (Table 3) [64,77–79]. In par-
icular, encouraging data have been observed in a phase II
rial using MGN1703 as maintenance treatment in patients
ith disease control of advanced CRC. The findings from
his study suggest that one avenue for further exploration
f this immunotherapy may be in settings with a reduced
umor burden. In particular, MGN1703 may be beneficial to
hose patients who experience significant tumor shrinkage
ollowing induction therapy [64]. IMPALA, a phase III trial
f MGN1703 in the first-line/maintenance setting in patients
ith metastatic CRC, is underway. The IMPALA study
ill take place in eight European countries and will enroll
40 patients who achieved tumor reduction after receiving
rst-line chemotherapy with or without biological agents
ClinicalTrials.gov Identifier: NCT02077868). Results from
his study, which are expected in late 2017, will offer fur-
her insight into the therapeutic potential for MGN1703 as
n alternative cancer immunotherapy.
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